Webinars and Commercial Conversations — Register Now

Tuesday, December 1, 2026, 1 PM-2 PM ET

Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.

Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, January 12, 2027, 2 PM-3 PM ET
Hear Dr. Roden discuss how computational pathology will impact the practice & future of precision oncology, using global real world analytical evidence for the novel TROP2 NMR biomarker as an example.

Webinar presenter Anja C. Roden, MD, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science, Rochester, Minnesota

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Roche Diagnostics. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Waters launches Xevo TQ Absolute XR IVD mass spectrometer

November 2026—Waters Corp. launched the Xevo TQ Absolute XR IVD mass spectrometer, expanding its MassTrak IVD system portfolio of LC-MS/MS systems. Developed for routine laboratory testing requiring in vitro diagnostic–compliant systems, and built on the performance of the Xevo TQ Absolute IVD mass spectrometer, the new system delivers trace-level analytical performance in complex biological matrices.

Zepto awarded NIAID contract valued at up to $8.9 million

November 2026—Zepto Life Technology has been awarded a contract valued at up to $8.9 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the company’s plasma cell-free DNA liquid biopsy platform for invasive fungal infections. The contract supports the development of Zepto’s integrated molecular diagnostic system, including a planned multicenter clinical study designed to support a future FDA submission if project milestones are met.

Siemens releases CN-3000, CN-6000 hemostasis systems

November 2026—Siemens Healthineers has released the CN-3000 and CN-6000 automated hemostasis analyzers for mid- and high-volume laboratories in the United States. The systems bring clotting, chromogenic, immunoassay, and platelet aggregation (for research use only) methodologies onto a compact platform.

ARUP study underscores value of atypical cfDNA results

November 2026—A research study by ARUP Laboratories clarifies the clinical value of atypical findings from prenatal cell-free DNA screening and their impact on pregnancy outcomes. The study, which investigated the connection between atypical prenatal cfDNA screening results and the diagnostic yield of follow-up testing, found that atypical findings frequently indicate clinically relevant diagnoses.

BioFire panels get IVDR class D CE mark

November 2026—BioMérieux’s BioFire Respiratory 2.1 Plus and BioFire FilmArray Pneumonia Plus panels have received the CE mark under the IVDR as class D in vitro diagnostic devices. The classification is driven by the inclusion of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) on both test menus.

NeoGenomics launches prostate cancer CDx

November 2026—NeoGenomics launched the PTEN IHC CDx, an immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The assay detects PTEN protein loss in prostate adenocarcinoma tissue using the Ventana PTEN (SP218) RxDx assay to identify patients who may be eligible for AstraZeneca’s FDA-approved targeted therapy Truqap (capivasertib).

Roche gets CE mark for latent TB blood test

November 2026—The Roche Elecsys IGRA TB test for identifying tuberculosis infection has received the CE mark. The Elecsys IGRA TB test runs on Cobas immunoassay systems and provides results in less than 24 hours. The interferon gamma release assay takes 19 minutes per patient to process and is designed to integrate with third-party automated liquid handlers for front-end processes prior to tube incubation.

Roche gets FDA clearance for Cobas BV/CV assay

November 2026—Roche received FDA 510(k) clearance for its Cobas BV/CV assay. It uses real-time polymerase chain reaction technology to identify the bacteria and yeast responsible for bacterial vaginosis and Candida vaginitis from symptomatic patients.

FDA clears QIAstat-Dx bloodstream infection panel

November 2026—The FDA has cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The panel detects 20 Gram-positive bacterial and fungal pathogen targets as well as a broad pan Gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples in about one hour.

NanoSomix, Beckman to develop neurodegenerative disease assays

October 2026—NanoSomix and Beckman Coulter Diagnostics are collaborating to explore the development of next-generation immunoassays for neurodegenerative diseases. The companies share an interest in addressing challenges in detecting low-abundance, brain-specific biomarkers in blood.